Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

H Lundbeck A s patents

Recent patent applications related to H Lundbeck A s. H Lundbeck A s is listed as an Agent/Assignee. Note: H Lundbeck A s may have other listings under different names/spellings. We're not affiliated with H Lundbeck A s, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | H Lundbeck A s-related inventors




Date H Lundbeck A s patents (updated weekly) - BOOKMARK this page
11/30/172-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
11/16/175-ht6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbiity
11/09/172-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
11/02/172-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
11/02/17Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
10/26/17Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
10/19/17Triazolopyrazinones as pde1 inhibitors
10/12/17Process for the manufacture of idalopirdine via hydrogenation of an imine
10/12/171,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
10/12/17Imidazopyrazinones as pde1 inhibitors
09/28/17Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption
09/21/17Quinazolin-thf-amines as pde1 inhibitors
09/21/17Agents, uses and methods for treatment
08/24/17N-substituted-5-substituted phthalamic acids as sortilin inhibitors
08/24/17Modulation of the vps10p-domain receptor family for the treatment of mental and behavioural disorders
08/10/17Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
08/03/17Bicyclo[3.2.1]octyl amide derivatives and uses of same
07/20/17Benzamides-containing compounds and their use in the treatment of epilepsy
06/22/17Substituted imidazo[1,5-a]pyrazines as pde9 inhibitors
06/08/17Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
06/08/17Modulation of activity of neurotrophins
06/01/17Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-2,2,3,3-tetrafluoropropoxy)benzylamine hydrochoride for the treatment of alzheimer's
05/11/17Cyclic amines
03/30/17Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
03/23/17New positive allosteric modulators or nicotinic acetylcholine receptor
03/23/17Pde9 inhibitors with imidazo triazinone backbone
03/09/172-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
02/23/17Non-neurotoxic plasminogen activating factors for treating of stroke
02/16/17Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
02/16/17Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
02/16/172-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
02/09/17Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine
01/26/17Halogenated quinazolin-thf-amines as pde1 inhibitors
01/26/17Antibodies specific to pyroglutamated abeta
01/19/17Antibodies specific for hyperphosphorylated tau and methods of use thereof
01/19/17Agents, uses and methods for the treatment of synucleinopathy
01/12/17Cyclic amines
12/29/16Nalmefene for reduction of alcohol consumption in specific target populations
12/22/16Vortioxetine pyroglutamate
12/08/16Methods of treating alzheimer's disease and pharmaceutical compositions thereof
12/01/16Hexahydrofuropyrroles as pde1 inhibitors
12/01/16Use of sortilin as biomarker for affective/mood disorders
11/10/16Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same
11/03/16Quinazolin-thf-amines as pde1 inhibitors
11/03/16Imidazopyrazinones as pde1 inhibitors
10/27/16Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
10/27/16Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
10/27/16Imidazotriazinones as pde1 inhibitors
10/20/16Quinoline derivatives as pde10a enzyme inhibitors
09/08/16Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
09/08/16Methods of treating alzheimer's disease and pharmaceutical compositions thereof
08/11/16Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
07/28/16Pde9 inhibitors with imidazo triazinone backbone
06/30/16Aminopyridine derived compounds as lrrk2 inhibitors
06/16/16Process for the manufacture of idalopirdine
06/09/16Dosage and use of an a2a antagonist
06/02/16Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption
05/19/16Phenyl-piperazine derivatives as serotonin reuptake inhibitors
05/12/162-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
04/14/16Arylpyrrolopyridine derived compounds as lrrk2 inhibitors
03/24/161-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
03/10/16Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
03/03/16Nalmefene for treatment of patients with mood disorder
03/03/16Nalmefene for treatment of patients with anxiety disorder
03/03/16Modulation of activity of proneurotrophins
Patent Packs
01/14/16Vortioxetine manufacturing process
12/31/15Quinoline derivatives as pde10a enzyme inhibitors
12/24/15N-substituted-5-substituted phthalamic acids as sortilin inhibitors
11/26/156-chloro-3-(phenyl-d5)-inden-1-one and use thereof
11/26/15Aminopyridine derived compounds as lrrk2 inhibitors
11/05/15New positive allosteric modulators of nicotinic acetylcholine receptor
10/29/15Cyclic amines
10/29/15Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
10/22/15Compositions comprising vortioxetine and donepezil
10/22/15Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
10/15/15Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
10/08/15Benzamides
10/01/15Pde9i with imidazo pyrazinone backbone
08/27/15Modulation of the interaction between sorla and gdnf-family ligand receptors
08/20/15Modulation of activity of neurotrophins
Patent Packs
08/20/15Positive allosteric modulators of nicotinic acetylcholine receptor
08/20/152-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
07/09/15Novel phenylimidazole derivatives as pde10a enzyme inhibitors
06/25/15Quinazolin-thf-amines as pde1 inhibitors
06/04/15Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
04/02/15Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
03/19/15Processes for the manufacture of a pharmaceutically active agent
03/19/15Sleep spindles as biomarker for early detection of neurodegenerative disorders
03/12/15Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine
02/26/15Bicyclo[3.2.1.]octyl amide derivatives and uses of same
02/12/15Pde9 inhibitors with imidazo triazinone backbone
01/22/15Modulation of activity of proneurotrophins
01/22/15Novel phenylimidazole derivatives as pde10a enzyme inhibitors
01/01/155-membered heterocyclic amides and related compounds
01/01/151-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
12/25/141-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
12/18/14Antibodies specific to pyroglutamated abeta
12/18/141-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
10/23/14Novel patient subgroups for thrombolysis
09/11/141-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
09/04/141-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
09/04/141-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
08/28/14Modulation of the vps10p-domain receptor family for the treatment of mental and behavioural disorders
08/21/14Pyridine compounds and uses thereof
07/17/14Non-neurotoxic plasminogen activating factors for treating of stroke
07/10/14Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
06/05/14Method for the manufacturing of naltrexone
04/17/14Cyclic amines
04/17/14Benzamides
03/13/14Methods of treating alzheimer's disease and pharmaceutical compositions thereof
Social Network Patent Pack
02/13/14New positive allosteric modulators of nicotinic acetylcholine receptor
02/06/14Heteroaryl amide analogues as p2x7 antagonists
01/02/14Tricyclic imidazole compounds as pde10 inhibitors
11/14/13Radiolabelled phenylimidazole-based ligands
10/03/13Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin
09/19/13Processes for the manufacture of a pharmaceutically active agent
09/05/132-substituted-ethynylthiazole derivatives and uses of same
08/22/13Combination of a serotonin reuptake inhibitor and agomelatine
08/15/13Process for the purification of pharmaceutically acceptable salts
07/25/13Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
Patent Packs
07/25/13Azaisoquinolinone derivatives as nk3 antagonists
07/18/13Adamantyl diamide derivatives and uses of same
07/18/13Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsuflanyl)phenyl]piperazine
07/04/13Heteroaryl amide derivatives
06/27/13Modulation of activity of neurotrophins
02/14/13Non-neurotoxic plasminogen activating factors for treating of stroke
01/10/13New positive allosteric modulators of nicotinic acetylcholine receptor
01/03/13New positive allosteric modulators of nicotinic acetylcholine receptor
12/06/12Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
12/06/12Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
11/29/122-arylimidazole derivatives as pde10a enzyme inhibitors
11/29/12Phenyl-piperazine derivatives as serotonin reuptake inhibitors
10/25/12Adamantyl diamide derivatives and uses of same
10/11/125-htp combination therapy
10/04/12Positive allosteric modulators of nicotinic acetylcholine receptor
08/30/12Novel carbamylated epo and its production
08/02/12Catecholamine derivatives and prodrugs thereof
07/26/12Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
07/26/12Heteroaryl amide analogues
07/26/12Novel phenylimidazole derivative as pde10a enzyme inhibitor
07/26/12Bicyclo[3.2.1]octyl amide derivatives and uses of same
06/28/12Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
06/07/12Manufacture of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl-piperazine
05/31/12Novel phenylimidazole derivatives as pde10a enzyme inhibitors
05/24/12Imidazole derivatives as pde10a enzyme inhibitors
05/17/12Preparation of nalmefene hydrochloride from naltrexone
05/10/12Method for the manufacturing of naltrexone
04/05/12Modulation of activity of neurotrophins
03/29/12Methods of administering (4ar,10ar)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof
02/09/12Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
Patent Packs
01/05/12Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
12/08/11Polymorphic forms of a gabaa agonist
12/01/11Substituted thiomorpholine derivatives
11/24/11Isoquinolinone derivatives as nk3 antagonists
10/13/11Nalmefene hydrochloride dihydrate
09/22/11Biologically active amides
09/15/11Azaisoquinolinone derivatives as nk3 antagonists
08/25/11Method for treating cognitive deficits
07/21/11Adamantyl diamide derivatives and uses of same
07/21/11Oral formulation
07/07/11Design and use of sortilin specific molecular imaging ligands
07/07/11Modulation of the vps10p-domain for the treatment of cardiovascular disease
06/30/11Design of specific ligands to sortilin
06/23/11Processes for the manufacture of a pharmaceutically active agent
06/16/11Modulation of the trpv: vps10p receptor system for the treatment of pain
06/16/11Pyridone derivatives as nk3 antagonists
06/02/11Isoquinolinone derivatives as nk3 antagonists
06/02/11Isoquinolinone derivatives as nk3 antagonists
05/05/11Method of upregulating sorla for the treatment of alzheimer's disease
04/28/11(3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
Social Network Patent Pack
04/28/11Spirolactam derivatives and uses of same
04/21/112-substituted-ethynylthiazole derivatives and uses of same
03/17/11Method for the separation of intermediates which may be used for the preparation of escitalopram
03/17/11Method for the preparation of escitalopram
03/03/11Malonate salt of 4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same
03/03/11Process for the manufacture of [phenylsulfanylphenyl]piperidines
02/24/11Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
02/17/114-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
01/13/111- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
01/13/11Phenyl-piperazine derivatives as serotonin reuptake inhibitors
01/06/11Subsituted pyridine derivatives
12/23/10Processes for 4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof
11/25/101- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
11/18/105-membered heterocyclic amides and related compounds
11/11/10Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
11/11/10Combination therapy related to serotonin dual action compounds
10/07/10Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
08/26/10Heteroaryl amide derivatives
06/10/104- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
06/03/10Substituted pyrimidine derivatives
Social Network Patent Pack
06/03/104- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
04/29/10Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
04/29/10Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
04/15/10Treatment of impaired respiratory function with gaboxadol
03/25/10Isoquinolinone derivatives as nk3 antagonists
03/18/10Process for making trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
03/11/10Substituted morpholine and thiomorpholine derivatives
03/11/10Substituted aniline derivatives
01/28/10Adamantyl diamide derivatives and uses of same
01/21/10Novel phenylimidazole derivatives as pde10a enzyme inhibitors
12/31/09Novel phenolic and catecholic amines and prodrugs thereof
12/31/09[2-(6-fluoro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
12/17/09Novel down-regulation of amyloid
12/10/09Method for treating cognitive deficits
10/29/09Anti-manic effective doses of sertindole
10/22/09Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
10/22/09Method for manufacture of sertindole
10/22/09Process for alkyl aryl sulfide derivatives and new sulfide compounds
10/01/09N-thiazol-2-yl-benzamide derivatives
10/01/09Method for the preparation of escitalopram
08/27/09Uses of indane compounds
08/13/09Use of siramesine in the treatment of cancer
08/13/09Treatment of depression and other affective disorders
07/30/09Benzo[b]furane and benzo[b]thiophene derivatives
07/09/09Combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
06/04/09Modified absorption formulation of gaboxadol
06/04/09Methods of using substituted morpholine and thiomorpholine derivatives
06/04/09Isoquinolinone derivatives as nk3 antagonists
06/04/09Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
05/28/092-acylaminothiazole derivatives
Social Network Patent Pack
05/28/09Substituted morpholine and thiomorpholine derivatives
05/14/09Catecholamine derivatives and prodrugs thereof
05/14/09Methods and systems for treating illnesses
05/07/09Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
04/02/09Method for the preparation of citalopram
03/19/09Cyanoisoquinoline
03/12/09Method for manufacture of escitalopram
03/05/09Catecholamine derivatives and prodrugs thereof
02/26/09Method for identifying compounds for the treatment of depression
02/19/09Method of treating stress-mediated depression







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with H Lundbeck A s in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for H Lundbeck A s with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';